Cover Image
市场调查报告书

脂肪肉瘤 : 开发平台分析

Liposarcoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品编码 307305
出版日期 内容信息 英文 162 Pages
订单完成后即时交付
价格
Back to Top
脂肪肉瘤 : 开发平台分析 Liposarcoma - Pipeline Review, H2 2016
出版日期: 2016年12月14日 内容信息: 英文 162 Pages
简介

脂肪肉瘤是脂肪组织的恶性肿瘤。常见的症状有突出的疙瘩和肿起,疼痛,体重减少,腹痛等。原因有年龄,暴露于化学物质,放射线等。治疗方法包含化疗,放疗,外科手术。

本报告提供脂肪肉瘤的治疗药开发情形调查分析,提供您开发中产品概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势,最新消息和新闻稿等相关的系统性信息。

目录

简介

脂肪肉瘤概要

治疗药的开发

  • 开发中产品:概要
  • 开发中产品:比较分析

正在开发的治疗药:各企业

开发中产品的概要

  • 后期阶段的产品
  • 临床阶段的产品

开发中的产品:各企业

开发治疗药的企业

  • 第一三共
  • Immune Design Corp.
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Sanofi

治疗药的评估

  • 单独疗法的情况
  • 联合治疗的情况
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • cabazitaxel
  • efatutazone
  • everolimus
  • HDM-201
  • palbociclib
  • pazopanib hydrochloride
  • pembrolizumab
  • ribociclib
  • selinexor
  • trabectedin

开发中产品的最新趋势

暂停中的计划

开发中止的产品

产品开发的里程碑

  • 最新消息和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC8815IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liposarcoma - Pipeline Review, H2 2016, provides an overview of the Liposarcoma (Oncology) pipeline landscape.

Liposarcoma is a malignant tumor of fatty tissue. Symptoms include noticeable lump or swelling, pain, weight loss and abdominal pain. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liposarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liposarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liposarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liposarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 3 and 2 respectively.Liposarcoma.

Liposarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liposarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Liposarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liposarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liposarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liposarcoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liposarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liposarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liposarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Liposarcoma - Overview
  • Liposarcoma - Therapeutics under Development by Companies
  • Liposarcoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Liposarcoma - Products under Development by Companies
  • Liposarcoma - Companies Involved in Therapeutics Development
    • Adaptimmune Therapeutics Plc
    • Amgen Inc
    • Cellceutix Corp
    • Eli Lilly and Company
    • Horizon Pharma Plc
    • Immune Design Corp
    • Karyopharm Therapeutics Inc
    • Merck & Co Inc
    • Mirati Therapeutics Inc
    • Novartis AG
    • Pfizer Inc
  • Liposarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abemaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3377794 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HDM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon gamma-1b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ribociclib succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sitravatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vimo-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Liposarcoma - Dormant Projects
  • Liposarcoma - Discontinued Products
  • Liposarcoma - Product Development Milestones
    • Featured News & Press Releases
      • Nov 09, 2016: Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma
      • Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma
      • Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Liposarcoma, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Liposarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Liposarcoma - Pipeline by Amgen Inc, H2 2016
  • Liposarcoma - Pipeline by Cellceutix Corp, H2 2016
  • Liposarcoma - Pipeline by Eli Lilly and Company, H2 2016
  • Liposarcoma - Pipeline by Horizon Pharma Plc, H2 2016
  • Liposarcoma - Pipeline by Immune Design Corp, H2 2016
  • Liposarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Liposarcoma - Pipeline by Merck & Co Inc, H2 2016
  • Liposarcoma - Pipeline by Mirati Therapeutics Inc, H2 2016
  • Liposarcoma - Pipeline by Novartis AG, H2 2016
  • Liposarcoma - Pipeline by Pfizer Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Liposarcoma - Dormant Projects, H2 2016
  • Liposarcoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Liposarcoma, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top